

Remarks

This amendment is also made to conform the application with the provisions of 37 CFR §§1.821 through 1.825. A replacement Sequence Listing in computer readable format and on paper is attached. The numeric identifier <160> has been changed to 15 in order to show the total number of sequences contained in the sequence listing. The replacement Sequence Listing contains revisions to SEQ ID NOs: 1, 3, 4, 6, 7, 11, 12, and 13 to identify the starting position and ending position of the mature peptide sequence shown at numeric identifier <222>.

The numeric identifier <211> in SEQ ID NO: 5 and SEQ ID NO: 9 has been amended to reflect the correct number of amino acids contained in the sequence. SEQ ID NO: 6 has been amended to remove the extra <400> sequence identifier number.

The originally filed Sequence Listing contained two sequences identified as SEQ ID NO: 8. Applicants respectfully submit that the first SEQ ID NO: 8 having 91 amino acids is an exact duplicate of SEQ ID NO: 13 and the same has been deleted in this substitute sequence listing.

Applicants respectfully assert that these corrections are obvious inadvertent errors in the sequence, and Applicants respectfully submit that no new matter has been introduced by way of this correction to SEQ ID NO: 8.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachment: New pages 1-9 (Sequence Listing) of the subject specification